Result of AGM

RNS Number : 5005T

Oxford Cannabinoid Tech.Holdings

24 November 2021

 

Oxford Cannabinoid Technologies Holdings plc

Results of Annual General Meeting

Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company"), the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), (together, the "Group"), a company developing licensed prescription cannabinoid medicines for approval by regulatory agencies worldwide and targeting the U$ multi-billion pain market, announces that all of the resolutions set out in the notice of Annual General Meeting dated 27 October 2021 were duly passed at today's Annual General Meeting.

	Resolution	For (including discretionary)	%	Against	%	Total	% of ISC voted	Withheld*
1.	Receive and adopt the 2021 Annual Report and Accounts	434,161,471	100.00%	4,711	0.00%	434,166,182	45.21%	10,669
2.	Approve the Directors' Remuneration Report	415,591,935	96.31%	15,935,441	3.69%	431,527,376	44.93%	2,649,475
3.	Re-elect Charanjit Cheryl Dhillon	409,190,649	94.25%	24,973,423	5.75%	434,164,072	45.21%	12,779
4.	Re-elect Karen Lowe	434,159,361	100.00%	4,711	0.00%	434,164,072	45.21%	12,779
5.	Re-elect Dr. John Lucas	409,192,759	94.25%	24,973,423	5.75%	434,166,182	45.21%	10,669
6.	Re-elect Indraneil Mahapatra	356,013,210	82.00%	78,150,862	18.00%	434,164,072	45.21%	12,779
7.	Re-elect Bishrut Mukherjee	330,983,856	76.23%	103,180,216	23.77%	434,164,072	45.21%	12,779
8.	Re-elect Julie Patricia Pomeroy	409,122,643	94.23%	25,034,065	5.77%	434,156,708	45.21%	20,143
9.	Re-elect Gavin Hilary Sathianathan	354,174,790	99.48%	1,843,131	0.52%	356,017,921	37.07%	12,779
10.	Re-elect Clarissa Ann Sowemimo-Coker	409,190,649	94.25%	24,973,423	5.75%	434,164,072	45.21%	12,779
11.	Re-appoint Moore Kingston Smith LLP as auditor	434,161,471	100.00%	4,711	0.00%	434,166,182	45.21%	10,669
12.	Authorise the Directors to fix the auditor's remuneration	434,081,048	99.98%	85,134	0.02%	434,166,182	45.21%	10,669
13.	To authorise the Directors to allot ordinary shares or grant rights to subscribe for or to convert any security into ordinary shares, pursuant to Section 551 of the Companies Act 2006.	415,576,695	95.72%	18,589,487	4.28%	434,166,182	45.21%	10,669
14.	To authorise the Directors to disapply pre-emption rights (general authority).**	415,479,418	95.70%	18,667,400	4.30%	434,146,818	45.20%	30,033
15.	To authorise the Directors to disapply pre-emption rights (additional authority).**	415,545,060	95.71%	18,609,122	4.29%	434,154,182	45.20%	22,669
16.	That a general meeting other than an annual general meeting may be called on not less than 14 clear days' notice.**	433,954,746	99.97%	126,436	0.03%	434,081,182	45.20%	95,669

* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

** Indicates special resolutions requiring a 75% majority.

Given that all resolutions passed concern ordinary business, no submission will be made to the National Storage Mechanism in accordance with Listing Rule 14.3.6R(2). 

A copy of the Annual General Meeting results will be available on the Company's website at https://www.oxcantech.com/investor-financial-results-centre  

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this announcement.

Enquiries:

Oxford Cannabinoid Technologies Holdings plc Dr John Lucas (CEO) Clarissa Sowemimo-Coker (COO)	[phone] [e-mail] [e-mail]
Cairn Financial Advisers LLP Emily Staples Jo Turner	[phone] [phone]
Walbrook PR Limited Paul Vann Nicholas Johnson	[phone] [phone] [e-mail]

About Oxford Cannabinoid Technologies Holdings Plc :

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company of Oxford Cannabinoid Technologies Ltd ("OCT"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the U$ multi-billion pain market (together the "Group"). Cannabinoids are compounds found in the cannabis plant that have been shown to have a range of therapeutic effects on the body, including pain relief. The Group has a clearly defined path to commercialisation, revenues and growth.

The Group is developing drug candidates through clinical trials to gain regulatory approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe them with confidence.

The Group's portfolio aims to balance risk, value and time to market, whilst ensuring market exclusivity around all its key activities. The Group's lead compound, OCT461201, is a highly potent and selective CB2 agonist and is being developed by OCT in a solid oral dosage form. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022. The Group's product pipeline also uses a balanced drug product strategy that employs phytocannabinoids, cannabinoid derivatives and other novel compounds for the treatment of pain.

OCTP operates a partnership model with external academic and commercial partners, including the University of Oxford.

 

END

 

 

RAGUSOVRAAUAUAA